The environment as a source of mobilizable genes encoding antimicrobial resistance: the pan-microbial resistance genome (resistome) Metagenomic analysis and fully sequenced genomes of bacteria have provided new insights into the relationship between the ecology and genome evolution of bacteria. Genome analysis has revealed that genome size and gene content in bacteria are correlated with their lifestyles. 1 Bacteria can be classified according to their lifestyle as mutualistic (sympatric speciation) and parasitic (allopatric speciation) organisms. 1 The evolutionary transitions underlying pathogenic and symbiotic lifestyles are mainly due to gene transfer and gene loss occurring within bacterial lineages. Compared with free-living bacteria, host-dependent bacteria are characterized by specialization by massive gene loss and genome size reduction. 1 Conversely, genome sequence analysis has shown that evolutionary pressure exerted by an ecological niche selects for a similar genetic repertoire in those prokaryotes that occupy the same niche, and that this is due to both vertical and horizontal transmission. 2 Genetic diversity in independent genetic worlds could be considered as a network structure with many possibilities for genetic exchange between these genetic worlds, thanks to plasmids and phages. 3 Moreover, environmental microbial communities represent a huge reservoir of mobilizable genes-the so called mobilome-that includes a pool of genes encoding antimicrobial resistance-the resistome-that may penetrate from the pan-microbial genome into taxonomically and ecologically distant bacterial populations, including pathogens.
It is now accepted that environmental bacteria are more intrinsically resistant to antimicrobials compared with the commensal bacteria that are the main causes of infectious diseases, which contain only a tiny fraction of the resistome. 4 Moreover, the majority of the mechanisms of antimicrobial resistance in clinical isolates have originated from the environmental resistome and have been transferred to other bacteria through mobile genetic elements, including plasmids and/or phages. 4, 5 Recent functional metagenomic studies on soil samples revealed that soil bacteria display a high level of genetic diversity and are a reservoir of antimicrobial resistance genes. 6, 7 Similarly, it has been demonstrated recently that phages from environmental samples carry antimicrobial resistance genes that are able to confer antimicrobial resistance on bacterial strains. 8 Finally, human gut microbiota also carry antimicrobial resistance genes, as recently demonstrated by culture of human faecal microbiota. 9 Selective pressure provided by antimicrobials contributes considerably to the mobilization and distribution of antimicrobial resistance genes from the resistome throughout microbial populations. A genome sequence can be considered to be the result of adaptation in response to evolutionary pressure. Genetic mechanisms involved in the acquisition of antimicrobial resistance genes from the environmental 'resistome' by commensal and pathogenic bacteria are mainly driven by horizontal gene transfer (HGT), including transformation, conjugation and transduction. 3 Interestingly, it has recently been 10 Viruses, especially bacteriophages, have the ability to manipulate the life histories and evolution of their hosts in remarkable ways. 11 -13 Transduction is one of the most powerful means of dissemination of genes that allow bacteria to become more pathogenic and resistant to antimicrobials.
14 Recent data have demonstrated that HGT by phages is much more prevalent than previously thought and that the environment plays a critical role in the transfer of antimicrobial resistance determinants by phages. 8, 15 It has been demonstrated that bacteriophages in sewage and in environmental samples contribute to the spread of several b-lactamase genes. 8, 15 Similarly, bacteriophages have been shown to play a role in the transfer of antimicrobial resistance determinants in enterococci, especially in interspecies transduction. 16 Thus, current knowledge on extensive HGT and recombination processes in the prokaryotic world has led to the emergence of the concept of open compartments in microbial communities, with antimicrobial resistance being a consequence of evolution, ecology and gene exchanges in a specific niche. 3 These recent studies give new insights into mechanisms that could explain the emergence and diffusion of antimicrobial resistance in human bacterial pathogens. Besides the environmental resistome, there are other antimicrobial resistance gene pools, especially in humans, including gut microbiota 13, 17 and the respiratory tract microbiota, which may be exposed to antimicrobials. In this way, some infectious diseases may be defined as a prokaryotic community resulting from a complex genomic assembly within the environment rather than single pathogenic species. Thus, it is assumed that the size of a microbial community is correlated with the size of the mobilome, including the resistome, and the probability of having genetic exchanges that may influence the pan-microbial genome, leading to the adaptation of this microbial community to a specific niche under selective pressure.
Cystic fibrosis (CF) is a polymicrobial disease and the lung is the site of a specific microbiota for emergence of antimicrobial resistance CF, the most common genetic disease in Caucasian populations, is characterized by impaired mucociliary clearance, leading to colonization of the airways by pathogenic bacteria. 18 Repeated bronchopulmonary infections are responsible for a progressive decrease in the lung function and, eventually, death. Although the life expectancy of patients has increased to more than 36 years over the last decade, 19 mainly due to the improvement of care in specialized centres and intensive antimicrobial therapy, emerging multidrug-resistant pathogens are becoming more difficult to eradicate. 18 Recent studies of CF mucus by molecular methods have changed our thinking about CF lung infections. Besides the most commonly found pathogens (Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia cepacia complex, Haemophilus influenzae and atypical mycobacteria), analysis of mucus in CF airways has revealed the presence of a wide variety of bacteria at the same time, including anaerobes. 18, 20, 21 In our previous study using 16S PCR amplification, cloning and sequencing of 760 clones from 25 sputum samples from CF patients, we were able to detect 53 different bacterial species with a mean of about 7 different bacterial species per sputum sample. 20 Interestingly, the mean number of bacterial species detected increased when more clones were sequenced, indicating a huge complexity of microbial communities in these patients. 20 In a similar study, Harris et al.
21
detected 65 different bacterial species from 28 bronchoalveolar lavage samples from CF patients. Moreover, metagenomic analysis of DNA viruses in CF sputa highlighted the importance of the phage community in this niche. 22 It has been suggested that the human respiratory tract DNA virome in CF patients is defined by metabolism rather than by taxonomy, suggesting that CF therapeutics could be changed to focus on changing the environment of the airways rather than targeting specific common bacterial pathogens. 22 All these studies led us to consider CF mucus and airways as the site of a complex microbiota, where bacteria and viruses live together in a mutualistic lifestyle and adapt to their environment. This represents a new approach to the disease in which CF is considered a chronic disease with a complex microbial community resulting from genomic assemblage within the CF lung microbiota. Inside this microbiota, crosstalk between microbes and HGT are believed to contribute to the adaptation of bacteria to this specific environment over time, as in the human gut 23 or marine ecosystems. 24 In these communities with high levels of selective pressure, including antimicrobials, microbes must co-evolve and copy antimicrobial resistance strategies to compete for resources with microbial neighbours, mainly by HGT. Once the infection is installed in CF patients, eradication of these bacteria is impossible and iterative antimicrobial therapy is the rule, leading to the emergence of multidrug-resistant bacteria. Thus, lung infection and chronic colonization in CF patients is radically different from that of acute pneumonia, where only a few bacteria and viruses are pathogens. Moreover, the microbial community in the CF lung is highly variable over time and in relation to antimicrobial treatment and is probably linked to a balance between antimicrobial use and the acquisition of genes encoding antimicrobial resistance.
Bacterial genomes in CF patients are manipulated by phages
Whole-genome sequencing of many genomes of bacteria has recently demonstrated that lysogeny (integration of phage DNA into the bacterial chromosome as prophages) is a very frequent event, with many bacteria carrying multiple prophages. 13, 25 More specifically, phages are important vectors for the transfer of DNA between bacterial strains and contribute to the genetic individuality of a bacterial strain. 25 The presence of P. aeruginosa tailed phages in sputum samples from CF patients was reported previously, suggesting that they may play a role in the phenotypic changes of P. aeruginosa during chronic lung infection. 26 Moreover, fluctuations in phenotypes and genotypes within populations of P. aeruginosa in the CF lung during short periods of pulmonary exacerbation and intravenous antimicrobial therapy were found to be mainly due to widespread phage activity and genomic rearrangements. 27 Similarly, genome Review 2445 JAC analysis of strains of B. cepacia 28 and P. aeruginosa 29 isolated from CF patients revealed a particular genomic organization due to the presence of numerous prophages, which were demonstrated to be essential for the adaptation of these strains to the CF lung. Interestingly, the accessory genome of these CF strains contains many antimicrobial resistance genes as well as specific functions for adaptation specifically to the respiratory tract that were found to be encoded in prophages. 28 -30 Recently, we have also reported the detection of an original multidrug-resistant S. aureus strain (CF-Marseille) spreading in the CF community in Marseilles, France; this strain displayed a novel phenotype and presented a new phage closely related to phiETA3, suggested to be instrumental in acquired resistance. 30 Thus, phage mobilization is believed to contribute significantly to genome alteration in the context of CF.
The paradigm of antimicrobial treatment, phage induction and diffusion of antimicrobial resistance genes by transduction
There is now evidence that antimicrobials can cause phage induction in S. aureus and P. aeruginosa isolates from CF patients. 30, 31 We have reported that several antimicrobials commonly used in CF patients, including tobramycin, ciprofloxacin, co-trimoxazole and imipenem, are able to induce phages in S. aureus strain CF-Marseille. 30 Similarly, it was reported recently that ciprofloxacin could induce high levels of phage production in P. aeruginosa strains from CF patients. 31 Moreover, free phages from P. aeruginosa were detected directly in CF patient sputum samples by both plaque (40% positive) and PCR (76% positive) assays. 31 A recent study by Willner et al.
22 characterizing viral communities in CF patients versus non-CF patients demonstrated that the phage community was common to all CF patients and different from that of healthy subjects, and these phages presented with a specific metabolic profile reflecting adaptation to the particular nature of CF mucus. 22 Specifically, it was found that 16 059 annotated sequences were specific to the CF viromes, 32 including genes related to virulence. Annotation of sequences in the 'virulence' dataset identified many proteins associated with antimicrobial resistance genes. 32 Along with this review we report an original analysis of these specific sequences to reinforce our discussion (see article by Fancello et al. 33 in this issue). Looking at these specific sequences, we found that CF viromes contain a huge and significantly higher number of sequences putatively encoding resistance to antimicrobials from various origins (efflux pumps, fluoroquinolone resistance and b-lactamases) compared with non-CF viromes. 33 As CF patients are regularly treated with antimicrobials, we speculate that this phenomenon could explain in part the emergence of antimicrobial resistance via HGTand generalized transduction.
CF lung as a niche for creation of new species and multidrug-resistant bacteria with chimeric repertoires
Intensive antimicrobial therapy has undeniably increased the life expectancy of CF patients. 19 However, collateral effects of antimicrobial treatment, i.e. transduction of virulence genes or toxins or antimicrobial resistance determinants, often appear at concentrations subinhibitory for bacterial growth. 34 As antimicrobial treatment is adapted to the bacterium responsible for the disease, this situation may be considered unlikely from a clinical perspective. It is important to be aware that it can easily occur in CF, where bronchial exacerbation is now considered polymicrobial. 18 Indeed, antimicrobials employed in cystic fibrosis target the predominant bacterium found in sputum culture; in the case of a co-infection or co-colonization, antimicrobials which might be inefficient against, for example, S. aureus could be used to treat P. aeruginosa, and favour induction of S. aureus prophages.
These findings, along with genomic data, strongly suggest that the CF microbiota continuously generates new species, especially multidrug-resistant bacteria with chimeric repertoires, as exemplified by genome analysis of S. aureus, 30 P. aeruginosa 29 and B. cepacia 28 isolated from CF patients, which may be selected for their adaptation to this niche during the course of the disease and recurrent antimicrobial therapy. These new 'superbugs' may be able to spread in this community as well as on a worldwide scale. We postulate that CF patients have complex lung microbiota that include eukaryotes, bacteria, fungi and viruses within which there are many genetic exchanges occurring by HGT, especially generalized transduction due to antimicrobial treatment and selective pressure, which promote both the emergence and selection of multidrug-resistant bacteria that may spread in this population and the evolution of the microbial community that is specific to the disease. This paradigm is very similar to that of amoebas as a melting pot for the creation of new species with chimeric repertoires that may succeed and be selected if adapted in a specific niche. 35 Further work is needed to isolate and characterize phage particles containing genes encoding antimicrobial resistance directly from sputum samples and test their ability to transduce the antimicrobial resistance determinants to diverse host strains, as recently demonstrated in bacteriophages from environmental samples. 8 If phages are induced by antimicrobials among this complex microbiota, including bacteria, fungi and viruses, we can imagine the innumerable possibilities of HGT, particularly in the presence of phages with broad host range, which are able to transduce genes between different species. As phages are already known to be mobilized during chronic infection of the lungs of patients with CF, it seems particularly important to improve our understanding of the mechanisms of phage induction in order to prevent the spread of virulence and/or antimicrobial resistance determinants within CF population as well as in the community. These findings are of great concern for clinical practice in the future since current antimicrobial therapy guidelines in the context of CF may lead to the emergence and spread of genes encoding antimicrobial resistance.
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